Histone deacetylases and mechanisms of regulation of gene expression.

In recent years it has become widely recognized that histone modification plays a pivotal role in controlling gene expression and is involved in a wide spectrum of disease regulation. Histone acetylation is a major modification that affects gene transcription and is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs acetylate lysines of histone proteins, resulting in the relaxation of chromatin structure, and they also facilitate gene activation. Conversely, HDACs remove acetyl groups from hyperacetylated histones and suppress general gene transcription. In addition to histones, numerous nonhistone proteins can be acetylated and deacetylated, and they also are involved in the regulation of a wide range of diseases. To date there are 18 HDACs in mammals classified into 4 classes based on homology to yeast HDACs. Accumulating evidence has revealed that HDACs play crucial roles in a variety of biological processes including inflammation, cell proliferation, apoptosis, and carcinogenesis. In this review we summarize the current state of knowledge of HDACs in carcinogenesis and describe the involvement of HDACs in cancer-associated molecular processes. It is hoped than an understanding of the role of HDACs in cancer will lead to the design of more potent and specific drugs targeting selective HDAC proteins for the treatment of the disease.

[1]  Charles Giardina,et al.  HDAC3 overexpression and colon cancer cell proliferation and differentiation , 2008, Molecular carcinogenesis.

[2]  J. Mariadason,et al.  Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy , 2007, Cancer biology & therapy.

[3]  Andrew J. Wilson,et al.  Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy , 2012, Journal of Ovarian Research.

[4]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Natoli,et al.  Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages , 2012, Proceedings of the National Academy of Sciences.

[6]  H. Moon,et al.  A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  I. Irminger-Finger,et al.  HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b , 2013, PloS one.

[8]  I. Christensen,et al.  Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas , 2009, Histopathology.

[9]  J. Nam,et al.  Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. , 2008, Journal of gynecologic oncology.

[10]  N. Rosen,et al.  An acetylation site in the middle domain of Hsp90 regulates chaperone function. , 2007, Molecular cell.

[11]  Zhi-xiang Shen,et al.  Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma , 2013, Journal of Hematology & Oncology.

[12]  T. Shiozawa,et al.  Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.

[13]  E. Olson,et al.  Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development , 2009, Proceedings of the National Academy of Sciences.

[14]  E. Seto,et al.  The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.

[15]  H. Lehr,et al.  Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice , 2008, Gut.

[16]  Jay L. Morris,et al.  Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. , 2013, Anticancer research.

[17]  S. Hiebert,et al.  Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks , 2008, The EMBO journal.

[18]  N. Sundaresan,et al.  SIRT3 Is a Stress-Responsive Deacetylase in Cardiomyocytes That Protects Cells from Stress-Mediated Cell Death by Deacetylation of Ku70 , 2008, Molecular and Cellular Biology.

[19]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[20]  H. Nagase,et al.  Epigenetics: differential DNA methylation in mammalian somatic tissues , 2008, The FEBS journal.

[21]  M. Walther,et al.  The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. , 2013, Leukemia research.

[22]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[23]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Kristiansen,et al.  Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer , 2014, BMC Clinical Pathology.

[25]  Zhenhao Hua,et al.  Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. , 2010, Urologic oncology.

[26]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Izumi Horikawa,et al.  Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. , 2005, Molecular biology of the cell.

[28]  Carsten Denkert,et al.  Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression , 2013, BMC Cancer.

[29]  Eric Verdin,et al.  Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.

[30]  G. Feldmann,et al.  The NAD+-dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca2+ Responses* , 2012, The Journal of Biological Chemistry.

[31]  C. Jacobs,et al.  The epigenetic mechanism of mechanically induced osteogenic differentiation. , 2010, Journal of biomechanics.

[32]  Ming-Shiang Wu,et al.  Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma , 2010, Autophagy.

[33]  Limei Liu,et al.  Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. , 2013, Cancer letters.

[34]  J. Cheong,et al.  Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. , 2009, BMB reports.

[35]  C. Busch,et al.  Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. , 2013, The Journal of nutritional biochemistry.

[36]  R. Place,et al.  miR-449a targets HDAC-1 and induces growth arrest in prostate cancer , 2009, Oncogene.

[37]  W. Weichert,et al.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.

[38]  W. Liao,et al.  E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors , 2013, BMC Cancer.

[39]  S. Wang,et al.  SIRT1 interacts with p73 and suppresses p73‐dependent transcriptional activity , 2007, Journal of cellular physiology.

[40]  Cheng-Ping Yu,et al.  SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin , 2012, Pathology & Oncology Research.

[41]  Andrew J. Wilson,et al.  HDAC4 promotes growth of colon cancer cells via repression of p21. , 2008, Molecular biology of the cell.

[42]  R. Behringer,et al.  Regulation of NF-κB Circuitry by a Component of the Nucleosome Remodeling and Deacetylase Complex Controls Inflammatory Response Homeostasis* , 2010, The Journal of Biological Chemistry.

[43]  O. Witt,et al.  HDAC11 is a novel drug target in carcinomas , 2013, International journal of cancer.

[44]  A. Wróbel,et al.  Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. , 2014, Toxicology letters.

[45]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[46]  Xue-Ru Wu,et al.  The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo , 2007, Journal of Translational Medicine.

[47]  W. Weichert,et al.  Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. , 2008, Neoplasia.

[48]  S. Zhuang,et al.  HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome‐dependent pathway , 2011, Journal of cellular biochemistry.

[49]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[50]  R. Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy , 2007, Expert opinion on investigational drugs.

[51]  Le Wang,et al.  Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer , 2011, Journal of hematology & oncology.

[52]  Brigitte Schlegelberger,et al.  Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. , 2012, Gastroenterology.

[53]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[54]  Sung-Dae Cho,et al.  A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells. , 2013, Molecular medicine reports.

[55]  W. Gerald,et al.  Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. , 2009, American journal of translational research.

[56]  G. Packham,et al.  The NF-κB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes , 2010, Journal of hepatology.

[57]  M. Duvic,et al.  Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.

[58]  G. Bartsch,et al.  HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions , 2013, Experimental biology and medicine.

[59]  A. Lutz,et al.  Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators , 2014, Psychoneuroendocrinology.

[60]  Gordon B Mills,et al.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.

[61]  H. Sitter,et al.  Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC , 2011, Virchows Archiv.

[62]  V. Steele,et al.  Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APCmin/+ Mouse Intestinal Tumorigenesis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[63]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[64]  Guo-Zhong Ji,et al.  Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. , 2013, International journal of molecular medicine.

[65]  K. Nave,et al.  HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination , 2011, Nature Neuroscience.

[66]  Z. Herceg,et al.  Epigenetic interplay between histone modifications and DNA methylation in gene silencing. , 2008, Mutation research.

[67]  J. Turnay,et al.  Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells. , 2012, Biochimica et biophysica acta.

[68]  W. Ellmeier,et al.  Conditional Deletion of Histone Deacetylase 1 in T Cells Leads to Enhanced Airway Inflammation and Increased Th2 Cytokine Production , 2010, The Journal of Immunology.

[69]  W. Grizzle,et al.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. , 2011, International journal of oncology.

[70]  Delong Liu,et al.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.

[71]  L. Altucci,et al.  A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. , 2013, Blood.

[72]  G. Kristiansen,et al.  Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma , 2010, Expert opinion on therapeutic targets.

[73]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[74]  E. Olson,et al.  Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. , 2008, The Journal of clinical investigation.